T cells that recognize HER2 teceptor may prevent HER2+ breast cancer recurrence

Posted · Add Comment

Recurrence of HER2-positive breast cancer after treatment may be due to a specific and possibly cancer-induced weakness in the patient’s immune system — a weakness that in principle could be corrected with a HER2-targeted vaccine — according to a new study.

This full article appears on <a href="http://www.sciencedaily.com/releases/2015/12/151230143816.htm">Science Daily</a>

Leave a Reply

Your email address will not be published. Required fields are marked *